Superworth

Impact Biomedical revenue IBO

Sales by quarter and over the last twelve months, from 2022.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
$3K
−57% on a year earlier
Fiscal year 2022
$50K

Impact Biomedical's twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was $3K, down 57% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2022$50Kn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$3K−57%n/a
Q1 FY26$7Kn/an/a
Q3 FY25$18Kn/an/a
Q2 FY25$7Kn/an/a
Q4 FY22$0n/a$50K
Q3 FY22$0n/an/a
Q2 FY22$50Kn/an/a
Q1 FY22$0n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Impact Biomedical's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
IBOImpact Biomedicaln/m
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
NATRNatures Sunshine Products$492M+7% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
ABUSArbutus Biopharma$181.7M
AMPHAmphastar Pharmaceuticals$730M+1% a year
OMEROmerosn/m
Peer median$389.3M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Impact Biomedical

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.